Innovations
Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST
Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.
Read
Commented by Armin Schulz on April 2nd, 2024 | 06:45 CEST
MorphoSys, Defence Therapeutics, Novo Nordisk - Biotech deals: Corporations on a shopping spree!
In 2023, the volume of business in the pharmaceutical industry, with mergers and acquisitions, reached USD 152 billion despite high interest rates. Experts predict that this momentum could continue as large pharmaceutical companies are facing a wave of patent expiries for their key products that will roll in between 2025 and 2030. Companies are therefore on the lookout for new active ingredients, often by acquiring or licensing developments from smaller biotech companies to compensate for potential revenue shortfalls. There have also been major takeovers in recent months. We take a look at takeover targets and buyers.
Read
Commented by André Will-Laudien on March 19th, 2024 | 06:30 CET
Pay attention now - 100% performance possible with BioNTech, Bayer, Cardiol Therapeutics or HelloFresh
For investors in the biotech sector, 2024 is starting much like the previous year ended. Everyone is waiting for the big bang, which has yet to materialize. However, now that there is no longer a pandemic and cancer research is still stuck in a rut, selection has become crucial. Investing only in the future is no longer a guarantee of profit; instead, it is much more important to identify the most innovative business models and follow them. BioNTech does not currently have a blockbuster but has a good EUR 17 billion in its coffers. Bayer has seen its share price drop fivefold since 2019, and HelloFresh is also unable to keep its promises. By contrast, Cardiol Therapeutics has experienced a true rally. What lies next here?
Read
Commented by Juliane Zielonka on March 15th, 2024 | 06:00 CET
Altech Advanced Materials, Tesla, E.ON - Accelerators of the Future in Europe
Germany's automotive industry is in a state of upheaval. With an annual turnover of EUR 411 billion, solutions are urgently needed to drive electrification forward. E.ON, as one of the largest utilities, is investing billions in European infrastructure for this purpose. The Company is also increasing its dividend. Heidelberg-based Altech Advanced Materials is launching stationary battery storage systems on the market at the beginning of April. It has also published the results of the current feasibility study for its second pillar: a special coating for silicon battery anodes that ensures greater power and longevity. These are exactly the sticking points that customers have been complaining about so far. Tesla also relies on silicon batteries in its models. This week, Elon Musk visited the German plant in Grünheide, and has some good news in store...
Read
Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET
Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?
Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.
Read
Commented by Armin Schulz on February 28th, 2024 | 07:15 CET
Varta Thriller! Altech Advanced Materials, BYD work on the electrification of the future
While production at Varta is at a standstill following a cyber attack, the wave of electrification is rolling inexorably through our society, changing how we generate, store and utilize energy. Innovations are needed here, especially in energy storage from renewable sources and the further development of batteries for use in electric vehicles. Advances in electric vehicles and the increasing use of electrical energy are paving the way towards the future. Intensive research is currently being carried out on technologies that will increase both the effectiveness and capacity of battery systems. Altech Advanced Materials and BYD stand out here.
Read
Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET
Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?
It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.
Read
Commented by Juliane Zielonka on February 8th, 2024 | 07:00 CET
Innovation and expansion in energy supply: Mercedes-Benz, Altech Advanced Materials and Alibaba in focus
Energy supply is one of the top issues for investors. A reliable energy supply promotes stable business conditions and supports economic growth. While the opposite is true in Germany, companies like Mercedes-Benz are focusing on lucrative projects abroad. A joint venture with China to expand charging stations is on the Stuttgart-based company's agenda. The German company Altech Advanced Materials is committed to a secure and affordable energy supply. Together with Fraunhofer IKTS, they are developing a stationary ceramic solid-state battery based on salt, especially for critical infrastructure facilities such as hospitals. This enables a smooth, vital power supply for intensive care units, even in emergencies. While Mercedes-Benz is currently eyeing China, the retail giant Alibaba is publishing its quarterly figures this week, serving as an indicator of the country's economic development. The details are summarized below.
Read
Commented by Stefan Feulner on February 7th, 2024 | 07:00 CET
Novo Nordisk, Cardiol Therapeutics, Morphosys - Biotechs on a high
After a disappointing stock market year 2023, there is a gold-rush mood in the biotechnology and pharmaceutical sectors. Big names such as Eli Lilly, Vertex, Amgen and Novartis are going from high to high and possess enormous momentum. Acquisitions have also increased dramatically in recent months. The takeover prices are usually significantly higher than the current share prices of the listed companies. This wave will likely increase further due to the pressure that pharmaceutical giants are feeling as licenses expire.
Read
Commented by Stefan Feulner on January 30th, 2024 | 07:15 CET
Bayer, Defence Therapeutics, Morphosys - Biotech sector still on the upswing
The market is currently in an exceptional phase in the biotechnology sector. Following the record year of 2023, the number of M&A transactions continues to increase in the current year. The reason is clear. Many pharmaceutical giants are under pressure due to the expiration of many patents for high-revenue drugs. On the other hand, smaller, innovative companies are trading at attractive valuation levels following the corrections of recent years. In previous transactions, the acquirers paid significantly more than the current market value.
Read